Celltrion, Inc. (068270.KS)
KRW 193100.0
(-3.06%)
KRW 193100.0
(-3.06%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 99.13 Billion KRW | -35.82% |
| 2022 | 154.46 Billion KRW | -11.61% |
| 2021 | 174.75 Billion KRW | -13.89% |
| 2020 | 202.95 Billion KRW | 41.86% |
| 2019 | 143.06 Billion KRW | 38.79% |
| 2018 | 103.08 Billion KRW | -54.0% |
| 2017 | 224.1 Billion KRW | 7.76% |
| 2016 | 207.96 Billion KRW | -23.23% |
| 2015 | 270.9 Billion KRW | -38.62% |
| 2014 | 441.36 Billion KRW | 22.65% |
| 2013 | 359.86 Billion KRW | 37.55% |
| 2012 | 261.63 Billion KRW | 138.96% |
| 2011 | 109.48 Billion KRW | -27.98% |
| 2010 | 152.02 Billion KRW | 24.31% |
| 2009 | 122.3 Billion KRW | 195.81% |
| 2008 | 41.34 Billion KRW | 365.61% |
| 2007 | 8.87 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 81.83 Billion KRW | -17.45% |
| 2024 Q2 | 38.86 Billion KRW | -52.51% |
| 2023 Q2 | 173.14 Billion KRW | 17.04% |
| 2023 Q3 | 119.39 Billion KRW | -31.05% |
| 2023 Q1 | 147.94 Billion KRW | -4.23% |
| 2023 Q4 | 99.13 Billion KRW | -16.97% |
| 2023 FY | 99.13 Billion KRW | -35.82% |
| 2022 Q3 | 177.98 Billion KRW | -0.37% |
| 2022 Q4 | 154.46 Billion KRW | -13.21% |
| 2022 Q2 | 178.64 Billion KRW | 4.85% |
| 2022 FY | 154.46 Billion KRW | -11.61% |
| 2022 Q1 | 170.37 Billion KRW | -2.51% |
| 2021 Q3 | 178.5 Billion KRW | -0.91% |
| 2021 Q4 | 174.75 Billion KRW | -2.1% |
| 2021 Q1 | 189.96 Billion KRW | -6.4% |
| 2021 Q2 | 180.13 Billion KRW | -5.18% |
| 2021 FY | 174.75 Billion KRW | -13.89% |
| 2020 FY | 202.95 Billion KRW | 41.86% |
| 2020 Q2 | 78.73 Billion KRW | -45.42% |
| 2020 Q1 | 144.27 Billion KRW | 0.85% |
| 2020 Q4 | 202.95 Billion KRW | 169.05% |
| 2020 Q3 | 75.43 Billion KRW | -4.2% |
| 2019 Q3 | 157.47 Billion KRW | -1.32% |
| 2019 Q2 | 159.57 Billion KRW | 48.01% |
| 2019 FY | 143.06 Billion KRW | 38.79% |
| 2019 Q1 | 107.8 Billion KRW | 4.59% |
| 2019 Q4 | 143.06 Billion KRW | -9.15% |
| 2018 Q1 | 208.77 Billion KRW | -6.84% |
| 2018 Q4 | 103.08 Billion KRW | -6.8% |
| 2018 Q3 | 110.6 Billion KRW | -14.55% |
| 2018 FY | 103.08 Billion KRW | -54.0% |
| 2018 Q2 | 129.44 Billion KRW | -38.0% |
| 2017 FY | 224.1 Billion KRW | 7.76% |
| 2017 Q2 | 272.43 Billion KRW | 24.96% |
| 2017 Q3 | 224.26 Billion KRW | -17.68% |
| 2017 Q4 | 224.1 Billion KRW | -0.07% |
| 2017 Q1 | 218 Billion KRW | 4.83% |
| 2016 Q3 | 181.08 Billion KRW | 5.71% |
| 2016 Q4 | 207.96 Billion KRW | 14.84% |
| 2016 Q1 | 179.2 Billion KRW | -33.85% |
| 2016 FY | 207.96 Billion KRW | -23.23% |
| 2016 Q2 | 171.3 Billion KRW | -4.41% |
| 2015 Q4 | 270.9 Billion KRW | -10.18% |
| 2015 Q3 | 301.62 Billion KRW | -2.71% |
| 2015 FY | 270.9 Billion KRW | -38.62% |
| 2015 Q2 | 310.01 Billion KRW | 34.07% |
| 2015 Q1 | 231.23 Billion KRW | -47.61% |
| 2014 Q3 | 369.3 Billion KRW | -2.7% |
| 2014 Q2 | 379.53 Billion KRW | -3.83% |
| 2014 FY | 441.36 Billion KRW | 22.65% |
| 2014 Q4 | 441.36 Billion KRW | 19.51% |
| 2014 Q1 | 394.64 Billion KRW | 9.66% |
| 2013 FY | 359.86 Billion KRW | 37.55% |
| 2013 Q4 | 359.86 Billion KRW | -10.8% |
| 2013 Q3 | 403.44 Billion KRW | -16.16% |
| 2013 Q2 | 481.17 Billion KRW | -5.95% |
| 2013 Q1 | 511.64 Billion KRW | 95.56% |
| 2012 Q4 | 261.63 Billion KRW | 0.0% |
| 2012 Q1 | 102.68 Billion KRW | 0.0% |
| 2012 FY | 261.63 Billion KRW | 138.96% |
| 2011 Q1 | 161.98 Billion KRW | 6.55% |
| 2011 FY | 109.48 Billion KRW | -27.98% |
| 2011 Q3 | 132.09 Billion KRW | 40.68% |
| 2011 Q2 | 93.89 Billion KRW | -42.03% |
| 2010 Q1 | 127.05 Billion KRW | 3.89% |
| 2010 Q4 | 152.02 Billion KRW | 23.64% |
| 2010 FY | 152.02 Billion KRW | 24.31% |
| 2010 Q3 | 122.95 Billion KRW | -20.15% |
| 2010 Q2 | 153.97 Billion KRW | 21.19% |
| 2009 Q3 | 141.8 Billion KRW | 40.08% |
| 2009 Q2 | 101.23 Billion KRW | 373.8% |
| 2009 Q1 | 21.36 Billion KRW | -48.32% |
| 2009 FY | 122.3 Billion KRW | 195.81% |
| 2009 Q4 | 122.3 Billion KRW | -13.76% |
| 2008 Q3 | 41.32 Billion KRW | 1364.34% |
| 2008 Q1 | 5.16 Billion KRW | 0.0% |
| 2008 FY | 41.34 Billion KRW | 365.61% |
| 2008 Q2 | 2.82 Billion KRW | -45.4% |
| 2008 Q4 | 41.34 Billion KRW | 0.05% |
| 2007 Q3 | 9.92 Billion KRW | 9.87% |
| 2007 Q1 | 5.12 Billion KRW | 0.0% |
| 2007 Q2 | 9.03 Billion KRW | 76.39% |
| 2007 FY | 8.87 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | 2.43 Billion KRW | -3968.562% |
| Green Cross Holdings Corporation | 216.35 Billion KRW | 54.18% |
| Green Cross Holdings Corporation | 84.89 Billion KRW | -16.778% |
| Pharmicell Co., Ltd. | 390.21 Million KRW | -25304.492% |
| Green Cross Corporation | 84.89 Billion KRW | -16.778% |
| GeneOne Life Science, Inc. | 6.27 Billion KRW | -1480.368% |
| Samsung Biologics Co.,Ltd. | 377.39 Billion KRW | 73.732% |
| SK bioscience Co.,Ltd. | 12.43 Billion KRW | -697.14% |
| SK Biopharmaceuticals Co., Ltd. | 94.48 Billion KRW | -4.92% |
| Prestige BioPharma Limited | 40.87 Billion KRW | -142.549% |